Bullish Case: CMS has rebounded +9.1% from the early-October low ($65.07) to $70.97, and the Helium return surface clusters mass at small positive returns, consistent with mean-reverting grind-higher behavior. Helium's +2.03% AI forecast, cheap near-the-money call convexity (Dec 75C at 15.6% IV vs. 50P puts at 54.7%), and Helium-vs-market IV edge (+2%) favor modest upside drift. Q4 earnings (late January) with a $24B capital plan supports rate-base growth toward the high-$70s.

Bearish Case: Seeking Alpha's Hold rating with a $54 target questions whether the $24B capital plan earns its cost of capital; P/B of 3.1 leaves little valuation cushion. Helium's price-density shows fat left tails below $65, deep-put IV richness persists (Dec 50P/55P at 59-107% IV), and the Helium-market IV gap widens with time-to-expiry (0.0 to 0.118 over the sampled 17-21 day window), signaling Helium sees underpriced tail uncertainty the market misses. Prior 50%+ rangebound calls were validated, but downside triggers never fired—complacency risk.

Potential Outcomes:

1. 45%: Rangebound $68-74 through February — return-surface density peaks near small returns; falsified by sustained trade below $67 or above $75.
2. 20%: Upside to $76-82 — benign Q4 earnings/regulatory clarity; requires holding >$72 with call-IV compression; falsified by rejection at $74.
3. 18%: Downside to $63-67 — rate-case/financing headlines; confirmed by persistent put-IV richness while price slides below $68.
4. 12%: IV spike >50% with flat price — event-driven repricing around hearings/filings; falsifiable if IV stays under 40%.
5. 5%: Tail shock ≤-20% — operational/legal shock; would show abrupt cross-strike IV elevation.

November 05, 2026